Amdinocillin
Coactin (amdinocillin) is a small molecule pharmaceutical. Amdinocillin was first approved as Coactin on 1984-12-21. It is used to treat bacterial infections, escherichia coli infections, gram-negative bacterial infections, klebsiella infections, and urinary tract infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | 2 | 3 | 1 | 7 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 2 | 2 | 1 | 5 |
| Communicable diseases | D003141 | — | — | — | 1 | 2 | 1 | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | 1 | — | 1 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | — | — | 1 | — | 1 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | — | 1 | — | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | 1 | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | 1 | — | 1 |
| Antibiotic prophylaxis | D019072 | — | — | — | — | — | 1 | — | 1 |
| Cystectomy | D015653 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chlamydia infections | D002690 | EFO_0007205 | A74.9 | — | 1 | — | — | — | 1 |
| Urethritis | D014526 | EFO_0003878 | N34 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amdinocillin |
| INN | mecillinam |
| Description | Mecillinam is a penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria. It has a role as an antibacterial drug and an antiinfective agent. |
| Classification | Small molecule |
| Drug class | penicillins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N2[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 32887-01-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL530 |
| ChEBI ID | — |
| PubChem CID | 36273 |
| DrugBank | DB01163 |
| UNII ID | V10579P3QZ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,819 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
192 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use